LQDA
Liquidia Corporation
NASDAQ · Healthcare · Biotechnology · US
$68.66
+0.04%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
15.4x
EV/EBITDA
33.7x
Market Cap
$6.15B
MomentumView details →
1D Return
+0.04%
YTD Return
+99.80%
RSI (14)
40.5
ValuationView details →
P/E (Fwd)
15.4x
EV/EBITDA
33.7x
Market Cap
$6.15B
RSI (14)
40.5
MomentumView details →
1D Return
+0.04%
YTD Return
+99.80%
SummaryUpdated Jun 1, 2026
Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina. The company went public in July 2018 and focuses on developing and commercializing innovative treatments for rare diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia utilizes its proprietary PRINT technology platform to create precisely engineered drug particles that can improve the delivery and efficacy of existing medications.
Similar companies
Latest newsMore news →
On August 20, 2026, Liquidia Corp's shares fell 5.8% to $71.05, continuing a decline from its 52-week high of $93.61.15d agoLiquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially.23d agoLiquidia Corporation reported second quarter 2026 financial results, with YUTREPIA net product sales of approximately $170.4 million, net income of $74.7 million, and adjusted EBITDA of $96.3 million.23d ago